Immune Mediated Diseases and Immune Modulation in the Neurocritical Care Unit

Neurotherapeutics

Volumn 9, Issue 1, 2012, Pages 99-123

  von Geldern, Gloria ^a   McPharlin, Thomas ^b   Becker, Kyra ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune; Corticosteroids; Cyclophosphamide; Immunomodulation; Intravenous immunoglobulin; Plasmapheresis; Rituximab

Indexed keywords

AMYLOID BETA PROTEIN; AQUAPORIN 4; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOUBLE STRANDED DNA; FRESH FROZEN PLASMA; GLUTAMATE DECARBOXYLASE ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUTROPHIL CYTOPLASMIC ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTEOLIPID PROTEIN; RITUXIMAB; THYROGLOBULIN; THYROID PEROXIDASE; THYROTROPIN; VOLTAGE GATED POTASSIUM CHANNEL;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADRENAL INSUFFICIENCY; ANTIPHOSPHOLIPID ANTIBODY SYNDROME; ANTIPHOSPHOLIPID SYNDROME; AREFLEXIA; ARTIFICIAL VENTILATION; ASTHMA; ATAXIA; AUTOIMMUNE THYROIDITIS; BEHCET DISEASE; BRAIN BIOPSY; CAMPYLOBACTER JEJUNI; CENTRAL NERVOUS SYSTEM INFECTION; CEREBRAL SINUS THROMBOSIS; CEREBROSPINAL FLUID ANALYSIS; CHIARI FROMMEL SYNDROME; CHOREA; CHURG STRAUSS SYNDROME; CLAUDICATION; CLINICAL FEATURE; CLINICAL PRACTICE; CONSCIOUSNESS DISORDER; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS; DECOMPRESSIVE CRANIECTOMY; DIABETES INSIPIDUS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; EATON LAMBERT SYNDROME; ELECTROMYOGRAM; ENCEPHALOMYELITIS; EOSINOPHIL; EPSTEIN BARR VIRUS; ERYTHEMA NODOSUM; ERYTHROCYTE SEDIMENTATION RATE; ETHNICITY; GENITAL ULCER; GENOTYPE; GIANT CELL ARTERITIS; GUILLAIN BARRE SYNDROME; HAEMOPHILUS INFLUENZAE; HEADACHE; HEMIPARESIS; HERNIA; HERPES SIMPLEX VIRUS; HUMAN; HYPEREOSINOPHILIA; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFLUENZA VIRUS A H1N1; INTENSIVE CARE UNIT; INTRACRANIAL PRESSURE; JAW DISEASE; KERATOCONJUNCTIVITIS SICCA; LIFE EXPECTANCY; LUNG INFILTRATE; MAINTENANCE THERAPY; MEDICAL SOCIETY; MICROSCOPIC POLYANGIITIS; MONONEUROPATHY MULTIPLEX; MORBIDITY; MORTALITY; MOUTH INFLAMMATION; MOUTH ULCER; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; MUMPS VIRUS; MUSCLE RIGIDITY; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; MYCOPLASMA PNEUMONIA; MYELITIS; MYELOOPTIC NEUROPATHY; MYOCLONUS; MYOKYMIA; NEUROMONITORING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OPHTHALMOPLEGIA; OPTIC NEURITIS; PARANEOPLASTIC NEUROPATHY; PERIPHERAL NEUROPATHY; PERONEUS NERVE; PLASMAPHERESIS; PLEOCYTOSIS; PRIMARY ANGIITIS OF THE CENTRAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASMUSSEN SYNDROME; RESPIRATORY FAILURE; REVIEW; RHINORRHEA; RHINOSINUSITIS; SARCOIDOSIS; SEIZURE; SJOEGREN SYNDROME; STIFF MAN SYNDROME; STROKE; SUPERFICIAL TEMPORAL ARTERY; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX RADIOGRAPHY; THROMBOPHILIA; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; URINE SEDIMENT; UVEITIS; VASCULAR AMYLOIDOSIS; VISUAL DISORDER; VISUAL IMPAIRMENT; VITAMIN SUPPLEMENTATION; WEAKNESS; WEGENER GRANULOMATOSIS; XEROSTOMIA;

AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; CRITICAL CARE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; PLASMAPHERESIS;

EID: 84856566183     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-011-0096-3     Document Type: Review

References (389)

1. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9: 520-532.
2. Bronnum-Hansen H, Stenager E, Hansen T, Koch-Henriksen H. Survival and mortality rates among Danes with MS. Int MS J 2006; 13: 66-71.
3. Kingwell E, van der Kop M, Zhao Y, et al. Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. J Neurol Neurosurg Psychiatry 2011. doi: 10. 1136/jnnp-2011-300616.
4. Sumelahti ML, Hakama M, Elovaara I, Pukkala E. Causes of death among patients with multiple sclerosis. Mult Scler 2010; 16: 1437-1442.
5. Hader WJ. Disability and survival of multiple sclerosis in Saskatoon, Saskatchewan. Can J Neurol Sci 2010; 37: 28-35.
6. Grytten Torkildsen N, Lie SA, Aarseth JH, Nyland H, Myhr KM. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Mult Scler 2008; 14: 1191-1198.
7. Moldovan IR, Rudick RA, Cotleur AC, et al. Longitudinal single-cell cytokine responses reveal recurrent autoimmune myelin reactivity in relapsing - remitting multiple sclerosis patients. Mult Scler 2005; 11: 251-260.
8. Lalive PH, Menge T, Delarasse C, et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103: 2280-2285.
9. Lucchinetti CF, Brueck W, Rodriguez M, Lassmann H. Multiple sclerosis: lessons from neuropathology. Semin Neurol 1998; 18: 337-349.
10. Aktas O, Kieseier B, Hartung HP. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci 2010; 33: 140-152.
11. Bates D. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology 2011; 76: S14-S25.
12. Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol 2010; 9: 299-308.
13. Hu W, Lucchinetti CF. The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol 2009; 31: 439-453.
14. Enzinger C, Strasser-Fuchs S, Ropele S, et al. Tumefactive demyelinating lesions: conventional and advanced magnetic resonance imaging. Mult Scler 2005; 11: 135-139.
15. Malhotra HS, Jain KK, Agarwal A, et al. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy. Mult Scler 2009; 15: 193-203.
16. Cianfoni A, Niku S, Imbesi SG. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. AJNR Am J Neuroradiol 2007; 28: 272-277.
17. Ikeda K, Ito H, Hidaka T, et al. Repeated non-enhancing tumefactive lesions in a patient with a neuromyelitis optica spectrum disorder. Intern Med 2011; 50: 1061-1064.
18. Saiki S, Ueno Y, Moritani T, et al. Extensive hemispheric lesions with radiological evidence of blood-brain barrier integrity in a patient with neuromyelitis optica. J Neurol Sci 2009; 284: 217-219.
19. Park KY, Ahn JY, Cho JH, Choi YC, Lee KS. Neuromyelitis optica with brainstem lesion mistaken for brainstem glioma. Case report. J Neurosurg 2007; 107: 251-254.
20. Newey CR, Bermel RA. Fulminant cerebral demyelination in neuromyelitis optica. Neurology 2011; 77: 193.
21. Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000: CD001331.
22. Wiendl H, Toyka KV, Rieckmann P, et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008; 255: 1449-1463.
23. Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011; 76: 294-300.
24. Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008; 15: 893-908.
25. Gonzalez Sanchez JJ, Nora JE, de Notaris M, et al. A case of malignant monophasic multiple sclerosis (Marburg's disease type) successfully treated with decompressive hemicraniectomy. J Neurol Neurosurg Psychiatry 2010; 81: 1056-7.
26. Cabre P, Heinzlef O, Merle H, et al. MS and neuromyelitis optica in Martinique (French West Indies). Neurology 2001; 56: 507-514.
27. Cabrera-Gomez JA, Kurtzke JF, Gonzalez-Quevedo A, Lara-Rodriguez R. An epidemiological study of neuromyelitis optica in Cuba. J Neurol 2009; 256: 35-44.
28. Bizzoco E, Lolli F, Repice AM, et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 2009; 256: 1891-1898.
29. Asgari N, Lillevang ST, Skejoe HP, et al. A population-based study of neuromyelitis optica in Caucasians. Neurology 2011; 76: 1589-1595.
30. Collongues N, Marignier R, Zephir H, et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology 2010; 74: 736-742.
31. Wingerchuk DM. Neuromyelitis optica: effect of gender. J Neurol Sci 2009; 286: 18-23.
32. Cree BAC, Khan O, Bourdette D, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology 2004; 63: 2039-2045.
33. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010; 6: 383-392.
34. Saikali P, Cayrol R, Vincent T. Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica. Autoimmun Rev 2009; 9: 132-135.
35. Cayrol R, Saikali P, Vincent T. Effector functions of antiaquaporin-4 autoantibodies in neuromyelitis optica. Ann N Y Acad Sci 2009; 1173: 478-486.
36. Takano R, Misu T, Takahashi T, et al. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010; 75: 208-216.
37. Cabre P, Gonzalez-Quevedo A, Bonnan M, et al. Relapsing neuromyelitis optica: long term history and clinical predictors of death. J Neurol Neurosurg Psychiatry 2009; 80: 1162-1164.
38. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-815.
39. Cassinotto C, Deramond H, Olindo S, et al. MRI of the spinal cord in neuromyelitis optica and recurrent longitudinal extensive myelitis. J Neuroradiol 2009; 36: 199-205.
40. Pittock SJ, Weinshenker BG, Wijdicks EF. Mechanical ventilation and tracheostomy in multiple sclerosis. J Neurol Neurosurg Psychiatry 2004; 75: 1331-1333.
41. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53: 1107-1114.
42. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003; 60: 848-853.
43. Win17gerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
44. McKeon A, Fryer JP, Apiwattanakul M, et al. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol 2009; 66: 1134-1138.
45. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010; 17: 1019-1032.
46. Magana SM, Keegan BM, Weinshenker BG, et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 2011; 68: 870-878.
47. Carroll WM, Fujihara K. Neuromyelitis optica. Curr Treat Options Neurol; 12: 244-255.
48. Bedi GS, Brown AD, Delgado SR, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011; 17: 1225-1230.
49. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011; 76: 1310-1315.
50. Kim SH, Kim W, Park MS, et al. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 2011; 68: 473-479.
51. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009; 66: 1128-1133.
52. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011; 77: 659-666.
53. Leake JA, Albani S, Kao AS, et al. Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J 2004; 23: 756-764.
54. Panicker JN, Nagaraja D, Kovoor JM, Subbakrishna DK. Descriptive study of acute disseminated encephalomyelitis and evaluation of functional outcome predictors. J Postgrad Med 2010; 56: 12-16.
55. Sonneville R, Demeret S, Klein I, et al. Acute disseminated encephalomyelitisin the intensive care unit: clinical features and outcome of 20 adults. Intensive Care Med 2008; 34: 528-532.
56. Menge T, Hemmer B, Nessler S, et al. Acute disseminated encephalomyelitis: an update. Arch Neurol 2005; 62: 1673-1680.
57. Rossi A. Imaging of acute disseminated encephalomyelitis. Neuroimaging Clin N Am 2008; 18: 149-161.
58. Balasubramanya KS, Kovoor JM, Jayakumar PN, et al. Diffusion-weighted imaging and proton MR spectroscopy in the characterization of acute disseminated encephalomyelitis. Neuroradiology 2007; 49: 177-183.
59. Franciotta D, Columba-Cabezas S, Andreoni L, et al. Oligoclonal IgG band patterns in inflammatory demyelinating human and mouse diseases. J Neuroimmunol 2008; 200: 125-128.
60. Abou Zeid NE, Burns JD, Wijdicks EF, Giannini C, Keegan BM. Atypical acute hemorrhagic leukoencephalitis (Hurst's disease) presenting with focal hemorrhagic brainstem lesion. Neurocrit Care 2011; 12: 95-97.
61. Pinto PS, Taipa R, Moreira B, Correia C, Melo-Pires M. Acute hemorrhagic leukoencephalitis with severe brainstem and spinal cord involvement: MRI features with neuropathological confirmation. J Magn Reson Imaging 2011; 33: 957-91.
62. Davies NW, Sharief MK, Howard RS. Infection-associated encephalopathies: their investigation, diagnosis, and treatment. J Neurol 2006; 253: 833-845.
63. Probstel AK, Dornmair K, Bittner R, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 2011; 77: 580-588.
64. Brilot F, Dale RC, Selter RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009; 66: 833-942.
65. Selter RC, Brilot F, Grummel V, et al. Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases. Neurology 2010; 74: 1711-1715.
66. Di Pauli F, Mader S, Rostasy K, et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol 2011; 138: 247-254.
67. Zaguri R, Shelef I, Ifergan G, Almog Y. Fatal acute disseminated encephalomyelitis associated with cytomegalovirus infection. BMJ Case Rep 2009. doi: 10. 1136/bcr. 07. 2008. 0443.
68. Hofer M, Weber A, Haffner K, et al. Acute hemorrhagic leukoencephalitis (Hurst's disease) linked to Epstein-Barr virus infection. Acta Neuropathol 2005; 109: 226-230.
69. Kumar RS, Kuruvilla A. Teaching Neuroimages: acute hemorrhagic leukoencephalitis after mumps. Neurology 2009; 73: e98.
70. Kabakus N, Gurgoze MK, Yildirim H, Godekmerdan A, Aydin M. Acute hemorrhagic leukoencephalitis manifesting as intracerebral hemorrhage associated with herpes simplex virus type I. J Trop Pediatr 2005; 51: 245-249.
71. Fugate JE, Lam EM, Rabinstein AA, Wijdicks EF. Acute hemorrhagic leukoencephalitis and hypoxic brain injury associated with H1N1 influenza. Arch Neurol 2010; 67: 756-758.
72. Ahmed AI, Eynon CA, Kinton L, Nicoll JA, Belli A. Decompressive craniectomy for acute disseminated encephalomyelitis. Neurocrit Care 2010; 13: 393-395.
73. Dombrowski KE, Mehta AI, Turner DA, McDonagh DL. Life-saving hemicraniectomy for fulminant acute disseminated encephalomyelitis. Br J Neurosurg 2011; 25: 249-252.
74. Payne ET, Rutka JT, Ho TK, Halliday WC, Banwell BL. Treatment leading to dramatic recovery in acute hemorrhagic leukoencephalitis. J Child Neurol 2007; 22: 109-113.
75. Takata T, Hirakawa M, Sakurai M, Kanazawa I. Fulminant form of acute disseminated encephalomyelitis: successful treatment with hypothermia. J Neurol Sci 1999; 165: 94-97.
76. Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology 2001; 56: 1313-1318.
77. Bhat A, Naguwa S, Cheema G, Gershwin ME. The epidemiology of transverse myelitis. Autoimmun Rev 2010; 9: A395-A399.
78. de Seze J, Lanctin C, Lebrun C, et al. Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology 2005; 65: 1950-1953.
79. Young J, Quinn S, Hurrell M, Taylor B. Clinically isolated acute transverse myelitis: prognostic features and incidence. Mult Scler 2009; 15: 1295-1302.
80. Bruna J, Martinez-Yelamos S, Martinez-Yelamos A, Rubio F, Arbizu T. Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases. Mult Scler 2006; 12: 169-173.
81. D'Cruz DP, Mellor-Pita S, Joven B, et al. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol 2004; 31: 280-285.
82. Chen HC, Lai JH, Juan CJ, et al. Longitudinal myelitis as an initial manifestation of systemic lupus erythematosus. Am J Med Sci 2004; 327: 105-108.
83. Dolhun R, Sriram S. Neurosarcoidosis presenting as longitudinally extensive transverse myelitis. Journal of Clinical Neuroscience 2009; 16: 595-597.
84. Kerr DA, Ayetey H. Immunopathogenesis of acute transverse myelitis. Curr Opin Neurol 2002; 15: 339-347.
85. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878-886.
86. Greenberg BM, Thomas KP, Krishnan C, et al. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology 2007; 68: 1614-1617.
87. Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet 2005; 366: 1653-1666.
88. Chio A, Cocito D, Leone M, et al. Guillain-Barre syndrome: a prospective, population-based incidence and outcome survey. Neurology 2003; 60: 1146-1150.
89. Leis AA, Stokic DS. Neuromuscular Manifestations of Human West Nile Virus Infection. Curr Treat Options Neurol 2005; 7: 15-22.
90. Cabrera Serrano M, Rabinstein AA. Causes and outcomes of acute neuromuscular respiratory failure. Arch Neurol 2010; 67: 1089-1094.
91. Patel MB, Goyal SK, Punnam SR, et al. Guillain-Barre Syndrome with asystole requiring permanent pacemaker: a case report. J Med Case Reports 2009; 3: 5.
92. Minahan RE Jr., Bhardwaj A, Traill TA, Hanley DF. Stimulus-evoked sinus arrest in severe Guillain-Barre syndrome: a case report. Neurology 1996; 47: 1239-1242.
93. Bouget J, Chevret S, Chastang C, Raphael JC. Plasma exchange morbidity in Guillain-Barre syndrome: results from the French prospective, randomized, multicenter study. The French Cooperative Group. Crit Care Med 1993; 21: 651-658.
94. Maytal J, Eviatar L, Brunson SC, Gootman N. Use of demand pacemaker in children with Guillain-Barre syndrome and cardiac arrhythmias. Pediatr Neurol 1989; 5: 303-305.
95. Narayan D, Huang MT, Mathew PK. Bradycardia and asystole requiring permanent pacemaker in Guillain-Barre syndrome. Am Heart J 1984; 108: 426-428.
96. Emmons PR, Blume WT, DuShane JW. Cardiac monitoring and demand pacemaker in Guillain-Barre syndrome. Arch Neurol 1975; 32: 59-61.
97. Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev 2001: CD001798.
98. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2010: CD002063.
99. Hughes RA, Swan AV, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2010: CD001446.
100. Appropriate number of plasma exchanges in Guillain-Barré syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Ann Neurol 1997; 41: 298-306.
101. Souayah N, Nasar A, Suri MF, Qureshi AI. National trends in hospital outcomes among patients with Guillain-Barre syndrome requiring mechanical ventilation. J Clin Neuromuscul Dis 2008; 10: 24-28.
102. Alshekhlee A, Hussain Z, Sultan B, Katirji B. Immunotherapy for Guillain-Barre syndrome in the US hospitals. J Clin Neuromuscul Dis 2008; 10: 4-10.
103. Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry 1998; 64: 74-77.
104. Dhar R, Stitt L, Hahn AF. The morbidity and outcome of patients with Guillain-Barre syndrome admitted to the intensive care unit. J Neurol Sci 2008; 264: 121-128.
105. Kohrmann M, Huttner HB, Nowe T, Schellinger PD, Schwab S. Mechanical ventilation in Guillain-Barre syndrome: does age influence functional outcome? Eur Neurol 2009; 61: 358-363.
106. Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barre syndrome: incidence and mortality rates in US hospitals. Neurology 2008; 70: 1608-1613.
107. Ito M, Kuwabara S, Odaka M, et al. Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J Neurol 2008; 255: 674-682.
108. Odaka M, Yuki N, Yamada M, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain 2003; 126: 2279-2290.
109. Overell JR, Willison HJ. Recent developments in Miller Fisher syndrome and related disorders. Curr Opin Neurol 2005; 18: 562-586.
110. Odaka M, Yuki N, Hirata K. Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-Barre syndrome. J Neurol 2003; 250: 913-916.
111. Overell JR, Hsieh ST, Odaka M, Yuki N, Willison HJ. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database Syst Rev 2007: CD004761.
112. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol 2008; 7: 939-950.
113. Salvarani C, Brown RD, Jr., Calamia KT, et al. Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol 2007; 62: 442-451.
114. Hajj-Ali RA, Singhal AB, Benseler S, Molloy E, Calabrese LH. Primary angiitis of the CNS. Lancet Neurol 2011; 10: 561-572.
115. Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med 2007; 146: 34-44.
116. Ducros A, Boukobza M, Porcher R, et al. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain 2007; 130: 3091-3101.
117. Cupps TR, Moore PM, Fauci AS. Isolated angiitis of the central nervous system. Prospective diagnostic and therapeutic experience. Am J Med 1983; 74: 97-105.
118. Miller DV, Salvarani C, Hunder GG, et al. Biopsy findings in primary angiitis of the central nervous system. Am J Surg Pathol 2009; 33: 35-43.
119. Molloy ES, Hajj-Ali RA. Primary angiitis of the central nervous system. Curr Treat Options Neurol 2007; 9: 169-175.
120. Salvarani C, Brown RD, Jr., Calamia KT, et al. Efficacy of tumor necrosis factor alpha blockade in primary central nervous system vasculitis resistant to immunosuppressive treatment. Arthritis Rheum 2008; 59: 291-296.
121. Sen ES, Leone V, Abinun M, et al. Treatment of primary angiitis of the central nervous system in childhood with mycophenolate mofetil. Rheumatology (Oxford) 2010; 49: 806-811.
122. Chenevier F, Renoux C, Marignier R, et al. Primary angiitis of the central nervous system: response to mycophenolate mofetil. J Neurol Neurosurg Psychiatry 2009; 80: 1159-1161.
123. Scolding NJ, Joseph F, Kirby PA, et al. Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 2005; 128: 500-515.
124. Rigby H, Easton A, Bhan V. Amyloid beta-related Angiitis of the Central Nervous System: Report of 3 Cases. Can J Neurol Sci 2011; 38: 626-630.
125. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009; 73: 2061-2070.
126. Hermann DM, Keyvani K, van de Nes J, et al. Brain-reactive {beta}-amyloid antibodies in primary CNS angiitis with cerebral amyloid angiopathy. Neurology 2011; 77: 503-505.
127. DiFrancesco JC, Brioschi M, Brighina L, et al. Anti-A beta autoantibodies in the CSF of a patient with CAA-related inflammation: A case report. Neurology 2011; 76: 842-844.
128. Kinnecom C, Lev MH, Wendell L, et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology 2007; 68: 1411-1416.
129. Chung KK, Anderson NE, Hutchinson D, Synek B, Barber PA. Cerebral amyloid angiopathy related inflammation: three case reports and a review. J Neurol Neurosurg Psychiatry 2011; 82: 20-26.
130. Salvarani C, Brown RD, Jr., Calamia KT, et al. Primary central nervous system vasculitis: comparison of patients with and without cerebral amyloid angiopathy. Rheumatology (Oxford) 2008; 47: 1671-1677.
131. Kloppenborg RP, Richard E, Sprengers ME, et al. Steroid responsive encephalopathy in cerebral amyloid angiopathy: a case report and review of evidence for immunosuppressive treatment. J Neuroinflammation 2010; 7: 18.
132. Daniels R, Geurts JJ, Bot JC, Schonewille WJ, van Oosten BW. Steroid-responsive edema in CAA-related inflammation. J Neurol 2009; 256: 285-286.
133. Gonzalez-Gay MA, Garcia-Porrua C. Epidemiology of the vasculitides. Rheum Dis Clin North Am 2001; 27: 729-749.
134. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 2009; 88: 227-235.
135. Solans-Laque R, Bosch-Gil JA, Molina-Catenario CA, et al. Stroke and multi-infarct dementia as presenting symptoms of giant cell arteritis: report of 7 cases and review of the literature. Medicine (Baltimore) 2008; 87: 335-344.
136. Phillip R, Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol 2008; 26: S94-S104.
137. Lu-Emerson C, Walker M, Huber BR, et al. Lethal giant cell arteritis with multiple ischemic strokes despite aggressive immunosuppressive therapy. J Neurol Sci 2010; 295: 120-124.
138. Jennette JC. Nomenclature and classification of vasculitis: lessons learned from granulomatosis with polyangiitis (Wegener's granulomatosis). Clin Exp Immunol 2011; 164(suppl 1): 7-10.
139. Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med 2004; 117: 39-50.
140. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006; 368: 404-418.
141. Watts RA, Al-Taiar A, Scott DG, Macgregor AJ. Prevalence and incidence of Wegener's granulomatosis in the UK general practice research database. Arthritis Rheum 2009; 61: 1412-1416.
142. Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 2007; 46: 1329-1337.
143. Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE. Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 1993; 33: 4-9.
144. Holle JU, Gross WL. Neurological involvement in Wegener's granulomatosis. Curr Opin Rheumatol 2011; 23: 7-11.
145. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101-1107.
146. Chan M, Luqmani R. Pharmacotherapy of vasculitis. Expert Opin Pharmacother 2009; 10: 1273-1289.
147. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232.
148. Chen M, Kallenberg CG. ANCA-associated vasculitides--advances in pathogenesis and treatment. Nat Rev Rheumatol 2010; 6: 653-664.
149. Fortin PM, Tejani AM, Bassett K, Musini VM. Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis. Cochrane Database Syst Rev 2009: CD007057.
150. Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359: 2790-2803.
151. Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008; 67: 1004-1010.
152. Bosch X, Guilabert A, Espinosa G, Mirapeix E. Immunotherapy for antineutrophil cytoplasmic antibody-associated vasculitis: challenging the therapeutic status quo? Trends Immunol 2008; 29: 280-289.
153. Zhang W, Zhou G, Shi Q, et al. Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides. Clin Exp Rheumatol 2009; 27: S65-S69.
154. Ozkul A, Tataroglu C, Kiylioglu N, Akyol A. Microscopic polyangiitis presenting with medullary infarct. J Neurol Sci 2011; 300: 173-175.
155. Tang CW, Wang PN, Lin KP, et al. Microscopic polyangiitis presenting with capsular warning syndrome and subsequent stroke. J Neurol Sci 2009; 277: 174-175.
156. Isoda K, Nuri K, Shoda T, et al. Microscopic polyangiitis complicated with cerebral infarction and hemorrhage: a case report and review of literature. Nihon Rinsho Meneki Gakkai Kaishi 2010; 33: 111-115.
157. Ku BD, Shin HY. Multiple bilateral non-hemorrhagic cerebral infarctions associated with microscopic polyangiitis. Clin Neurol Neurosurg 2009; 111: 904-906.
158. Ito Y, Suzuki K, Yamazaki T, et al. ANCA-associated vasculitis (AAV) causing bilateral cerebral infarction and subsequent intracerebral hemorrhage without renal and respiratory dysfunction. J Neurol Sci 2006; 240: 99-101.
159. Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143: 632-638.
160. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78: 26-37.
161. Wolf J, Bergner R, Mutallib S, Buggle F, Grau AJ. Neurologic complications of Churg-Strauss syndrome--a prospective monocentric study. Eur J Neurol 2010; 17: 582-588.
162. Sehgal M, Swanson JW, DeRemee RA, Colby TV. Neurologic manifestations of Churg-Strauss syndrome. Mayo Clin Proc 1995; 70: 337-341.
163. Saech J, Owczarczyk K, Rosgen S, et al. Successful use of rituximab in a patient with Churg-Strauss syndrome and refractory central nervous system involvement. Ann Rheum Dis 2010; 69: 1254-1255.
164. Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant 2011; 26: 2865-2671.
165. Yurdakul S, Yazici H. Behcet's syndrome. Best Pract Res Clin Rheumatol 2008; 22: 793-809.
166. Al-Araji A, Kidd DP. Neuro-Behcet's disease: epidemiology, clinical characteristics, and management. Lancet Neurol 2009; 8: 192-204.
167. Davatchi F, Shahram F, Chams-Davatchi C, et al. Behcet's disease: from East to West. Clin Rheumatol 2010; 29: 823-833.
168. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet 1990; 335: 1078-1080.
169. Akman-Demir G, Bahar S, Coban O, Tasci B, Serdaroglu P. Cranial MRI in Behcet's disease: 134 examinations of 98 patients. Neuroradiology 2003; 45: 851-859.
170. Yesilot N, Mutlu M, Gungor O, et al. Clinical characteristics and course of spinal cord involvement in Behcet's disease. Eur J Neurol 2007; 14: 729-737.
171. Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behcet's disease: evaluation of 200 patients. The Neuro-Behcet Study Group. Brain 1999; 122 (pt 11): 2171-2182.
172. Siva A, Saip S. The spectrum of nervous system involvement in Behcet's syndrome and its differential diagnosis. J Neurol 2009; 256: 513-529.
173. Aguiar de Sousa D, Mestre T, Ferro JM. Cerebral venous thrombosis in Behcet's disease: a systematic review. J Neurol 2011; 258: 719-727.
174. Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol 2010; 94: 284-288.
175. Giardina A, Ferrante A, Ciccia F, et al. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behcet's disease refractory to standard immunosuppressive drugs. Rheumatol Int 2011; 31: 33-37.
176. Stam J, De Bruijn SF, DeVeber G. Anticoagulation for cerebral sinus thrombosis. Cochrane Database Syst Rev 2002: CD002005.
177. Saadoun D, Wechsler B, Desseaux K, et al. Mortality in Behcet's disease. Arthritis Rheum 2010; 62: 2806-2812.
178. Rybicki BA, Iannuzzi MC. Epidemiology of sarcoidosis: recent advances and future prospects. Semin Respir Crit Care Med 2007; 28: 22-35.
179. Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM 2009; 102: 449-460.
180. Joseph FG, Scolding NJ. Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatry 2009; 80: 297-304.
181. Hoitsma E, Drent M, Sharma OP. A pragmatic approach to diagnosing and treating neurosarcoidosis in the 21st century. Curr Opin Pulm Med 2010; 16: 472-479.
182. Terushkin V, Stern BJ, Judson MA, et al. Neurosarcoidosis: presentations and management. Neurologist 2010; 16: 2-15.
183. Murialdo G, Tamagno G. Endocrine aspects of neurosarcoidosis. J Endocrinol Invest 2002; 25: 650-662.
184. Bradley DA, Lower EE, Baughman RP. Diagnosis and management of spinal cord sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 58-65.
185. Fahoum F, Drory VE, Issakov J, Neufeld MY. Neurosarcoidosis presenting as Guillain-Barre-like syndrome. A case report and review of the literature. J Clin Neuromuscul Dis 2009; 11: 35-43.
186. Berhouma M, Abderrazek K, Krichen W, Jemel H. Apropos of an unusual and menacing presentation of neurosarcoidosis: the space-occupying trapped temporal horn. Clin Neurol Neurosurg 2009; 111: 196-199.
187. Westhout FD, Linskey ME. Obstructive hydrocephalus and progressive psychosis: rare presentations of neurosarcoidosis. Surg Neurol 2008; 69: 288-292.
188. Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis; 52: 336-346.
189. Lury KM, Smith JK, Matheus MG, Castillo M. Neurosarcoidosis--review of imaging findings. Semin Roentgenol 2004; 39: 495-504.
190. Tahmoush AJ, Amir MS, Connor WW, et al. CSF-ACE activity in probable CNS neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 191-197.
191. Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 2009; 72: 337-340.
192. Carter JD, Valeriano J, Vasey FB, Bognar B. Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med 2004; 117: 277-279.
193. Pettersen JA, Zochodne DW, Bell RB, Martin L, Hill MD. Refractory neurosarcoidosis responding to infliximab. Neurology 2002; 59: 1660-1661.
194. Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology 2010; 75: 568-570.
195. Sharma OP. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch Neurol 1998; 55: 1248-1254.
196. Swigris JJ, Olson AL, Huie TJ, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med 2011; 183: 1524-1530.
197. Hatron PY, Tillie-Leblond I, Launay D, et al. Pulmonary manifestations of Sjogren's syndrome. Presse Med; 40: e49-e64.
198. Gono T, Kawaguchi Y, Katsumata Y, et al. Clinical manifestations of neurological involvement in primary Sjogren's syndrome. Clin Rheumatol 2011; 30: 485-490.
199. Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjogren's syndrome. Autoimmun Rev 2010; 9: A305-A310.
200. Shapira Y, Agmon-Levin N, Shoenfeld Y. Geoepidemiology of autoimmune rheumatic diseases. Nat Rev Rheumatol 2010; 6: 468-476.
201. Massara A, Bonazza S, Castellino G, et al. Central nervous system involvement in Sjogren's syndrome: unusual, but not unremarkable--clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology (Oxford) 2010; 49: 1540-1549.
202. Niemela RK, Hakala M. Primary Sjogren's syndrome with severe central nervous system disease. Semin Arthritis Rheum 1999; 29: 4-13.
203. Rogers SJ, Williams CS, Roman GC. Myelopathy in Sjogren's syndrome: role of nonsteroidal immunosuppressants. Drugs 2004; 64: 123-132.
204. Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore) 2004; 83: 280-291.
205. Sanahuja J, Ordonez-Palau S, Begue R, Brieva L, Boquet D. Primary Sjogren Syndrome with tumefactive central nervous system involvement. AJNR Am J Neuroradiol 2008; 29: 1878-1879.
206. Chang Y, Horoupian DS, Lane B, et al. Inflammatory pseudotumor of the choroid plexus in Sjogren's disease. Neurosurgery 1991; 29: 287-290.
207. Pericot I, Brieva L, Tintore M, et al. Myelopathy in seronegative Sjogren syndrome and/or primary progressive multiple sclerosis. Mult Scler 2003; 9: 256-259.
208. Michel L, Toulgoat F, Desal H, et al. Atypical neurologic complications in patients with primary Sjogren's syndrome: report of 4 cases. Semin Arthritis Rheum 2010; 40: 338-342.
209. Segal B, Carpenter A, Walk D. Involvement of nervous system pathways in primary Sjogren's syndrome. Rheum Dis Clin North Am 2008; 34: 885-906.
210. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-558.
211. Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjogren's syndrome. Nat Clin Pract Rheumatol 2006; 2: 252-261.
212. Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010; 28: 468-476.
213. Chai J, Logigian EL. Neurological manifestations of primary Sjogren's syndrome. Curr Opin Neurol 2010; 23: 509-513.
214. Weng MY, Huang YT, Liu MF, Lu TH. Incidence and mortality of treated primary Sjogren's syndrome in Taiwan: a population-based study. J Rheumatol 2011; 38: 706-708.
215. Zhang W, Feng S, Yan S, et al. Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort. Rheumatology (Oxford) 2010; 49: 571-577.
216. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum 1999; 42: 1765-1772.
217. Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol 2010; 6: 358-367.
218. Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 2000; 59: 120-124.
219. Gibson T, Myers AR. Nervous system involvement in systemic lupus erythematosus. Ann Rheum Dis 1975; 35: 398-406.
220. Ansari A, Larson PH, Bates HD. Vascular manifestations of systemic lupus erythematosus. Angiology 1986; 37: 423-432.
221. Sibbitt WL Jr., Brooks WM, Kornfeld M, et al. Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus. Semin Arthritis Rheum 2010; 40: 32-52.
222. Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010; 69: 2074-2082.
223. Trevisani VF, Castro AA, Neves Neto JF, Atallah AN. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev 2006: CD002265.
224. Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 620-625.
225. Cervera R, Bucciarelli S, Plasin MA, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun 2009; 32: 240-245.
226. Bucciarelli S, Espinosa G, Cervera R, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006; 54: 2568-2576.
227. Espinosa G, Bucciarelli S, Asherson RA, Cervera R. Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors. Semin Thromb Hemost 2008; 34: 290-294.
228. Pons-Estel GJ, Salerni GE, Serrano RM, et al. Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: Report of 31 cases and review of the literature. Autoimmun Rev 2011; 10: 679-684.
229. Espinosa G, Berman H, Cervera R. Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev 2011; 10: 664-668.
230. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9: 776-785.
231. Lancaster E, Huijbers MG, Bar V, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011; 69: 303-311.
232. Bataller L, Galiano R, Garcia-Escrig M, et al. Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology 2010; 74: 265-267.
233. Boronat A, Sabater L, Saiz A, Dalmau J, Graus F. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 2011; 76: 795-800.
234. Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010; 67: 470-478.
235. Mata S, Muscas GC, Naldi I, et al. Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. J Neuroimmunol 2008; 199: 155-159.
236. Dalmau J. Recognizing paraneoplastic limbic encephalitis. J Clin Oncol 2009; 27: e230-e231.
237. Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011; 18: 19-27.
238. Kaymakamzade B, Kansu T, Tan E, Dericioglu N. LGI1 related limbic encephalitis and response to immunosuppressive therapy. J Neurol 2011 258: 2075-2077.
239. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010; 133: 2734-2748.
240. Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61: 25-36.
241. Wandinger KP, Saschenbrecker S, Stoecker W, Dalmau J. Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol 2010; 231: 86-91.
242. Tuzun E, Zhou L, Baehring JM, et al. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol 2009; 118: 737-743.
243. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10: 63-74.
244. Dalmau J. Status epilepticus due to paraneoplastic and nonparaneoplastic encephalitides. Epilepsia 2009; 50(suppl 12): 58-60.
245. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7: 1091-1098.
246. Chia PL, Tan K, Foo D. Profound Sinus Node Dysfunction in Anti-N-Methyl-D-Aspartate Receptor Limbic Encephalitis. Pacing Clin Electrophysiol 2011. doi: 10. 1111/j. 1540-8159. 2011. 03154. x.
247. McGinley J, McCabe DJ, Fraser A, et al. Hashimoto's encephalopathy; an unusual cause of status epilepticus. Ir Med J 2000; 93: 118.
248. Rekand T, Vedeler C, Gramstad A, Bindoff L. Hashimoto's encephalopathy: a treatable cause of mental impairment, stroke and seizures. Eur J Neurol 2003; 10: 746-747.
249. Bonmann E, Prumbaum M, Stippich C, Ringleb P, Sliwka U. Hashimoto encephalopathy: rare cause of stroke in young patient. Neurologist 2009; 15: 342-344.
250. Gucuyener K, Serdaroglu A, Bideci A, et al. Tremor and myoclonus heralding Hashimoto's encephalopathy. J Pediatr Endocrinol Metab 2000; 13: 1137-1141.
251. Castillo P, Woodruff B, Caselli R, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol 2006; 63: 197-202.
252. Castillo PR, Mignot E, Woodruff BK, Boeve BF. Undetectable CSF hypocretin-1 in "Hashimoto's encephalopathy" associated with coma. Neurology 2004; 62: 1909.
253. Sawka AM, Fatourechi V, Boeve BF, Mokri B. Rarity of encephalopathy associated with autoimmune thyroiditis: a case series from Mayo Clinic from 1950 to 1996. Thyroid 2002; 12: 393-398.
254. Schiess N, Pardo CA. Hashimoto's encephalopathy. Ann N Y Acad Sci 2008; 1142: 254-265.
255. Oide T, Tokuda T, Yazaki M, et al. Anti-neuronal autoantibody in Hashimoto's encephalopathy: neuropathological, immunohistochemical, and biochemical analysis of two patients. J Neurol Sci 2004; 217: 7-12.
256. Chen N, Qin W, Wei C, Wang X, Li K. Time course of Hashimoto's encephalopathy revealed by MRI: report of two cases. J Neurol Sci 2011; 300: 169-172.
257. Santoro D, Colombo I, Ghione I, et al. Steroid-responsive Hashimoto encephalopathy mimicking Creutzfeldt-Jakob disease. Neurol Sci 2011; 32: 719-722.
258. Doherty CP, Schlossmacher M, Torres N, et al. Hashimoto's encephalopathy mimicking Creutzfeldt-Jakob disease: brain biopsy findings. J Neurol Neurosurg Psychiatry 2002; 73: 601-602.
259. de Cerqueira AC, Bezerra JM, de Magalhaes GC, Rozenthal M, Nardi AE. Hashimoto's encephalopathy with clinical features similar to those of Creutzfeldt-Jakob disease. Arq Neuropsiquiatr 2008; 66: 903-905.
260. Spiegel J, Hellwig D, Becker G, Muller M. Progressive dementia caused by Hashimoto's encephalopathy-report of two cases. Eur J Neurol 2004; 11: 711-713.
261. Lopez-Giovaneli J, Moreaud O, Faure P, et al. Cortico-responsive encephalopathy associated with autoimmune thyroiditis (SREAT): about two case reports characterized by a gap between the diagnosis of autoimmune thyroiditis and neurological disorders. Ann Endocrinol (Paris) 2007; 68: 173-176.
262. Boers PM, Colebatch JG. Hashimoto's encephalopathy responding to plasmapheresis. J Neurol Neurosurg Psychiatry 2001; 70: 132.
263. Nieuwenhuis L, Santens P, Vanwalleghem P, Boon P. Subacute Hashimoto's encephalopathy, treated with plasmapheresis. Acta Neurol Belg 2004; 104: 80-83.
264. Nagpal T, Pande S. Hashimoto's encephalopathy: response to plasma exchange. Neurol India 2004; 52: 245-247.
265. Jacob S, Rajabally YA. Hashimoto's encephalopathy: steroid resistance and response to intravenous immunoglobulins. J Neurol Neurosurg Psychiatry 2005; 76: 455-456.
266. Tamura N, Matsudaira R, Hirashima M, et al. Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med 2007; 46: 409-414.
267. Hunter GR, Donat J, Pryse-Phillips W, Harder S, Robinson CA. Rasmussen's encephalitis in a 58-year-old female: still a variant? Can J Neurol Sci 2006; 33: 302-305.
268. Kupila L, Jutila L, Immonen A, et al. Late-onset Rasmussen's encephalitis and long-term remission. Epileptic Disord 2011; 13: 88-91.
269. Kashihara K, Ohno M, Takahashi Y. Twenty-one-year course of adult-onset Rasmussen's encephalitis and bilateral uveitis: case report. J Neurol Sci 2010; 294: 127-130.
270. Villani F, Pincherle A, Antozzi C, et al. Adult-onset Rasmussen's encephalitis: anatomical-electrographic-clinical features of 7 Italian cases. Epilepsia 2006; 47(suppl 5): 41-46.
271. McLachlan RS, Girvin JP, Blume WT, Reichman H. Rasmussen's chronic encephalitis in adults. Arch Neurol 1993; 50: 269-274.
272. Rogers SW, Andrews PI, Gahring LC, et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994; 265: 648-651.
273. Bien CG, Bauer J, Deckwerth TL, et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis. Ann Neurol 2002; 51: 311-318.
274. Mantegazza R, Bernasconi P, Baggi F, et al. Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol 2002; 131: 179-185.
275. Andrews PI, Dichter MA, Berkovic SF, Newton MR, McNamara JO. Plasmapheresis in Rasmussen's encephalitis. 1996. Neurology 2001; 57: S37-S41.
276. Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 2007; 21: S57-S107.
277. Muto A, Oguni H, Takahashi Y, et al. Nationwide survey (incidence, clinical course, prognosis) of Rasmussen's encephalitis. Brain Dev 2011; 32: 445-453.
278. Granata T, Fusco L, Gobbi G, et al. Experience with immunomodulatory treatments in Rasmussen's encephalitis. Neurology 2003; 61: 1807-1810.
279. Vincent A, McConville J, Farrugia ME, Newsom-Davis J. Seronegative myasthenia gravis. Semin Neurol 2004; 24: 125-133.
280. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 2010; 10: 46.
281. Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 2009; 72: 1548-1554.
282. Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365-368.
283. McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004; 55: 580-584.
284. Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011; 44: 36-40.
285. Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 1989; 52: 1121-1127.
286. Phillips LH. The epidemiology of myasthenia gravis. Semin Neurol 2004; 24: 17-20.
287. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002: CD002275.
288. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008; 23: CD002277.
289. Mandawat A, Kaminski HJ, Cutter G, Katirji B, Alshekhlee A. Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol 2010; 68: 797-805.
290. Wirtz PW, van Dijk JG, van Doorn PA, et al. The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands. Neurology 2004; 63: 397-398.
291. Nicolle MW, Stewart DJ, Remtulla H, Chen R, Bolton CF. Lambert-Eaton myasthenic syndrome presenting with severe respiratory failure. Muscle Nerve 1996; 19: 1328-1333.
292. Jiang JR, Shih JY, Wang HC, et al. Small-cell lung cancer presenting with Lambert-Eaton myasthenic syndrome and respiratory failure. J Formos Med Assoc 2002; 101: 871-874.
293. Tseng A, Claussen GC, Oh SJ. Respiratory failure in lambert-eaton myasthenic syndrome precipitated by calcium-channel blockers: report of a case and literature review. J Clin Neuromuscul Dis 2002; 4: 60-63.
294. Beydoun SR. Delayed diagnosis of Lambert-Eaton myasthenic syndrome in a patient presenting with recurrent refractory respiratory failure. Muscle Nerve 1994; 17: 689-690.
295. Barr CW, Claussen G, Thomas D, et al. Primary respiratory failure as the presenting symptom in Lambert-Eaton myasthenic syndrome. Muscle Nerve 1993; 16: 712-715.
296. Laroche CM, Mier AK, Spiro SG, et al. Respiratory muscle weakness in the Lambert-Eaton myasthenic syndrome. Thorax 1989; 44: 913-918.
297. Gracey DR, Southorn PA. Respiratory failure in Lambert-Eaton myasthenic syndrome. Chest 1987; 91: 716-718.
298. Collins LC. Respiratory failure secondary to Eaton-Lambert syndrome. J Ky Med Assoc 1986; 84: 665-666.
299. Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2011; 16: CD003279.
300. Dalakas MC, Fujii M, Li M, McElroy B. The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology 2000; 55: 1531-1535.
301. Jarius S, Stich O, Speck J, et al. Qualitative and quantitative evidence of anti-glutamic acid decarboxylase-specific intrathecal antibody synthesis in patients with stiff-person syndrome. J Neuroimmunol 2010; 229: 219-224.
302. Rizzi M, Knoth R, Hampe CS, et al. Long-lived plasma cells and memory B cells produce pathogenic anti-GAD65 autoantibodies in Stiff-Person Syndrome. PLoS One 2010; 5: e10838.
303. Holmoy T, Geis C. The immunological basis for treatment of stiff-person syndrome. J Neuroimmunol 2011; 231: 55-60.
304. Geis C, Weishaupt A, Hallermann S, et al. Stiff-person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain 2010; 133: 3166-3180.
305. Geis C, Beck M, Jablonka S, et al. Stiff-person syndrome associated anti-amphiphysin antibodies reduce GABA associated [Ca(2+)]i rise in embryonic motoneurons. Neurobiol Dis 2009; 36: 191-199.
306. Butler MH, Hayashi A, Ohkoshi N, et al. Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron 2000; 26: 307-312.
307. Mas N, Saiz A, Leite MI, et al. Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 2010; 82: 1399-1401.
308. Turner MR, Irani SR, Leite MI, et al. Progressive encephalomyelitis with rigidity and myoclonus: Glycine and NMDA receptor antibodies. Neurology 2011; 77: 439-443.
309. Qureshi A, Hennessy M. Stiff-person syndrome (SPS) complicated by respiratory failure: successful treatment with rituximab. J Neurol 2011. doi: 10. 1007/s00415-011-6123-9.
310. Dalakas MC, Fujii M, Li M, et al. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 2001; 345: 1870-1876.
311. Donofrio PD, Berger A, Brannagan TH, 3rd, et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve 2009; 40: 890-900.
312. Baker MR, Das M, Isaacs J, Fawcett PR, Bates D. Treatment of stiff-person syndrome with rituximab. J Neurol Neurosurg Psychiatry 2005; 76: 999-1001.
313. Hazin R, Abuzetun JY, Giglio P, Khan F. Agrypnia excitata: current concepts and future prospects in management. J Neuropsychiatry Clin Neurosci 2009; 21: 126-131.
314. Lugaresi E, Provini F. Agrypnia excitata: clinical features and pathophysiological implications. Sleep Med Rev 2001; 5: 313-322.
315. Lai C, Tian G, Takahashi T, et al. Neuromyelitis optica antibodies in patients with severe optic neuritis in China. J Neuroophthalmol 2011; 31: 16-19.
316. Vincent A, Irani SR. Caspr2 antibodies in patients with thymomas. J Thorac Oncol 2011; 5: S277-S280.
317. Merchut MP. Management of voltage-gated potassium channel antibody disorders. Neurol Clin 2010; 28: 941-959.
318. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17: 893-902.
319. Schroder A, Linker RA, Gold R. Plasmapheresis for neurological disorders. Expert Rev Neurother 2009; 9: 1331-1339.
320. Gross RA, Johnston KC. Levels of evidence: Taking Neurology to the next level. Neurology 2009; 72: 8-10.
321. Yuki N, Tagawa Y, Hirata K. Minimal number of plasma exchanges needed to reduce immunoglobulin in Guillain-Barre syndrome. Neurology 1998; 51: 875-877.
322. Kaplan AA, Halley SE. Plasma exchange with a rotating filter. Kidney Int 1990; 38: 160-166.
323. Dau PC. Increased proliferation of blood mononuclear cells after plasmapheresis treatment of patients with demyelinating disease. J Neuroimmunol 1990; 30: 15-21.
324. Glassman AB, Bennett CE. Alterations of lymphocyte responsiveness in Guillain-Barre syndrome. Effects of plasma exchange. Transfusion 1983; 23: 369-372.
325. Yoshii F, Shinohara Y. Impaired interleukin-2 response of mononuclear cells in Guillain-Barre syndrome. Eur J Neurol 2000; 7: 303-307.
326. Goto H, Matsuo H, Nakane S, et al. Plasmapheresis affects T helper type-1/T helper type-2 balance of circulating peripheral lymphocytes. Ther Apher 2001; 5: 494-496.
327. Chien PJ, Yeh JH, Chiu HC, et al. Inhibition of peripheral blood natural killer cell cytotoxicity in patients with myasthenia gravis treated with plasmapheresis. Eur J Neurol 2011; 18: 1350-1357.
328. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet 1997; 349: 225-230.
329. Lehmann HC, Hartung HP. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. J Neuroimmunol 2011; 231: 61-69.
330. Yeh JH, Chen WH, Chiu HC. Complications of double-filtration plasmapheresis. Transfusion 2004; 44: 1621-1625.
331. Couriel D, Weinstein R. Complications of therapeutic plasma exchange: a recent assessment. J Clin Apher 1994; 9: 1-5.
332. Lowenberg M, Stahn C, Hommes DW, Buttgereit F. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids 2008; 73: 1025-1029.
333. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-1723.
334. Gonzalo JA, Gonzalez-Garcia A, Martinez C, Kroemer G. Glucocorticoid-mediated control of the activation and clonal deletion of peripheral T cells in vivo. J Exp Med 1993; 177: 1239-1246.
335. Hetherington SV, Quie PG. Human polymorphonuclear leukocytes of the bone marrow, circulation, and marginated pool: function and granule protein content. Am J Hematol 1985; 20: 235-246.
336. Mager DE, Lin SX, Blum RA, Lates CD, Jusko WJ. Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol 2003; 43: 1216-1227.
337. Myhr KM, Mellgren SI. Corticosteroids in the treatment of multiple sclerosis. Acta Neurol Scand Suppl 2009: 73-80.
338. Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 2009; 103: 975-994.
339. Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 2011; 365: 62-70.
340. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96: 23-43.
341. Gauthier SA, Weiner HL. Cyclophosphamide therapy for MS. Int MS J 2005; 12: 52-58.
342. Perini P, Calabrese M, Rinaldi L, Gallo P. The safety profile of cyclophosphamide in multiple sclerosis therapy. Expert Opin Drug Saf 2007; 6: 183-190.
343. de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150: 670-680.
344. Adu D, Pall A, Luqmani RA, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 1997; 90: 401-109.
345. Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40: 2187-2198.
346. Drachman DB, Brodsky RA. High-dose therapy for autoimmune neurologic diseases. Curr Opin Oncol 2005; 17: 83-88.
347. Gladstone DE, Brannagan TH, 3rd, Schwartzman RJ, Prestrud AA, Brodsky I. High dose cyclophosphamide for severe refractory myasthenia gravis. J Neurol Neurosurg Psychiatry 2004; 75: 789-791.
348. Mok CC, To CH, Mak A, Poon WL. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol 2008; 35: 172-174.
349. Schwartzman RJ, Simpkins N, Alexander GM, et al. High-dose cyclophosphamide in the treatment of multiple sclerosis. CNS Neurosci Ther 2009; 15: 118-127.
350. Le Guenno G, Mahr A, Pagnoux C, Dhote R, Guillevin L. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum 2011; 63: 1435-1445.
351. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 2009; 6: 638-647.
352. Hartung HP. Advances in the understanding of the mechanism of action of IVIg. J Neurol 2008; 255(suppl 3): 3-6.
353. Gold R, Stangel M, Dalakas MC. Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues. Nat Clin Pract Neurol 2007; 3: 36-44.
354. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 513-33.
355. Jacobs BC, O'Hanlon GM, Bullens RW, et al. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 2003; 126: 2220-2234.
356. Zhang G, Lopez PH, Li CY, et al. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain 2004; 127: 1085-1100.
357. Piepers S, Jansen MD, Cats EA, et al. IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN. J Neuroimmunol 2010; 229: 256-262.
358. Yuki N, Watanabe H, Nakajima T, Spath PJ. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2011; 82: 87-91.
359. Le Pottier L, Sapir T, Bendaoud B, et al. Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann N Y Acad Sci 2007; 1110: 426-432.
360. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat Clin Pract Rheumatol 2007; 3: 262-272.
361. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8: 34-47.
362. Tackenberg B, Jelcic I, Baerenwaldt A, et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A 2009; 106: 4788-4792.
363. Creange A, Gregson NA, Hughes RA. Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcgammaRII expression in patients with chronic inflammatory neuropathies. J Neuroimmunol 2003; 135: 91-95.
364. Sharief MK, Ingram DA, Swash M, Thompson EJ. I. v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome. Neurology 1999; 52: 1833-1838.
365. Exley AR, Smith N, Winer JB. Tumour necrosis factor-alpha and other cytokines in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 1994; 57: 1118-1120.
366. Chen C, Danekas LH, Ratko TA, Vlasses PH, Matuszewski KA. A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centers. Ann Pharmacother 2000; 34: 295-299.
367. Fergusson D, Hutton B, Sharma M, et al. Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review. Transfusion 2005; 45: 1640-1657.
368. Hughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2006: CD002063.
369. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007; 68: 837-841.
370. Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 2004; 63: 2028-2033.
371. Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005; 64: 804-810.
372. Sahlas DJ, Miller SP, Guerin M, Veilleux M, Francis G. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology 2000; 54: 1370-1372.
373. Fu DC, Montgomery JR. High-dose, rapid-infusion IVIG in postvaccination acute disseminated encephalomyelitis. Neurology 2008; 71: 294-295.
374. Ravaglia S, Piccolo G, Ceroni M, et al. Severe steroid-resistant post-infectious encephalomyelitis: general features and effects of IVIg. J Neurol 2007; 254: 1518-1523.
375. Shahar E, Andraus J, Savitzki D, Pilar G, Zelnik N. Outcome of severe encephalomyelitis in children: effect of high-dose methylprednisolone and immunoglobulins. J Child Neurol 2002; 17: 810-814.
376. Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis 2005; 16: 313-318.
377. Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 2007; 38: 122-132.
378. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29: 173-184.
379. Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol 1994; 97(suppl 1): 79-83.
380. Kosmidis ML, Dalakas MC. Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord; 3: 93-105.
381. Bielekova B, Becker BL. Monoclonal antibodies in MS: mechanisms of action. Neurology; 74(suppl 1): S31-S40.
382. Ferraro AJ, Drayson MT, Savage CO, MacLennan IC. Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab. Eur J Immunol 2008; 38: 292-298.
383. Reis EA, Athanazio DA, Lima I, et al. NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int 2009; 29: 469-475.
384. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103: 5941-5946.
385. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688.
386. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460-471.
387. Wang T, Weigt SS, Belperio JA, Lynch JP. Immunosuppressive and cytotoxic therapy: pharmacology, toxicities, and monitoring. Semin Respir Crit Care Med; 32: 346-370.
388. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-4840.
389. Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011; 68: 1156-1164.